来自:中国糖尿病资讯网 编辑:editor|点击数:|2012-09-24
【摘要】 目的 观察DPP-4抑制剂西格列汀对新诊断T2DM患者的疗效。 方法 40例新诊断的T2DM患者被随机分入2组,分别给予西格列汀和阿卡波糖单药治疗。 结果 12周治疗后两组HbA1c、FPG、2hPG及体重均明显减低,组间比较差异无统计学意义(P>0.05)。西格列汀组治疗后胰岛β细胞功能指数(HOMA-β)明显升高(P<0.01),阿卡波糖组胰岛素抵抗指数(HOMA-IR)和血脂谱明显改善(P<0.05)。 结论 西格列汀是一种安全有效的新型降糖药物。
【关键词】西格列汀;阿卡波糖;糖尿病
Comparison of effects of sitagliptin and acarbose on newly-diagnosed T2DM patients YE Xiao, ZHANG Qian, CAO Ying, et al. Department of Endocrinology and Metabolism, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China
Corresponding author: XUE Yao-ming, E-mail: xueyaoming@126.com
【Abstract】 Objective To observe the efficacy of DPP-4 inhibitor sitagliptin in treatment of newly-diagnosed T2DM patients. Methods Forty T2DM patients were randomly assigned to 2 groups: group A received sitagliptin 100mg and group B received acarbose 150~300mg daily for treatment. Results After the 12-week treatment, the levels of HbA1c, FPG, 2hPG, and body weight decreased significantly compared to baseline in both groups, and there was no significant difference between the 2 groups (P>0.05). HOMA-βincreased significantly in the sitagliptin group (P<0.01) and HOMA-IR and lipid profile were improved in the acarbose group (P<0.05). Conclusion Sitagliptin is an effective and safe new medicine in reducing plasma glucose.
【Key words】 Sitagliptin; Acarbose; Diabetes
版权所有:《中国糖尿病杂志》社 主管单位:中华人民共和国教育部 主办单位:北京大学
地址:北京市西城区大红罗厂街1号 邮编:100034 电话(传真):010-88505683
中国糖尿病杂志社版权所 京ICP备11029051号-1 Powered by JiuduCMS 技术支持:九度创想